2614. Demographic and Clinical Characteristics by Antiviral Prescription in Influenza-Positive Children who Presented to Seven US Emergency Departments
Author(s) -
Lubna Hamdan,
Varvara Probst,
Herdi Rahman,
Laura S Stewart,
Keerti L. Dantuluri,
Leigh M. Howard,
Andrew Speaker,
Peter G. Szilagyi,
Constance Ogokeh,
Geoffrey A. Weinberg,
Eileen J. Klein,
Leila C. Sahni,
Janet A. Englund,
John V. Williams,
Brian Rha,
Julie A. Boom,
Marian G. Michaels,
Rangaraj Selvarangan,
Christopher J Harrison,
Joana Y Lively,
Monica McNeal,
Angela P. Campbell,
Natasha Halasa
Publication year - 2019
Publication title -
open forum infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.546
H-Index - 35
ISSN - 2328-8957
DOI - 10.1093/ofid/ofz360.2292
Subject(s) - medicine , medical prescription , sore throat , pediatrics , emergency department , throat , emergency medicine , surgery , psychiatry , pharmacology
Background Antiviral (AV) therapy is recommended for children < 2 years, hospitalized, or with underlying conditions (UC) and suspected influenza (flu). We sought to compare demographic and clinical characteristics by AV prescription in flu-positive children who presented to the emergency department (ED) and determine the percentage of AV prescription in these high-risk children. Methods Children < 18 years who presented with respiratory symptoms and/or fever at seven New Vaccine Surveillance Network sites were enrolled. We conducted interviews, obtained mid-turbinate nasal and/or throat swabs for molecular flu testing (results unknown to providers), and reviewed medical charts for AV prescription after presenting to the ED. These are preliminary data. Results From December 2016 to June 2018, 9,524 subjects were enrolled and tested for flu; 1,260 (13%) were flu-positive by research testing; 54% were male, median age was 41 months, and 23% were prescribed an AV. The frequency of AV prescription differed by study site (Figure 1). Among research-tested flu-positive patients, AV were prescribed to 25% of children < 2 years, 31% of children with UC, and 51% admitted to the hospital from the ED (Table 1). Of the 388 (31%) clinically-tested flu-positive patients, 52%, 66%, and 77% of the same high-risk groups were prescribed an AV, respectively. Conclusion AV prescriptions varied by study site and differences by race, ethnicity, and clinical presentation were noted. Clinical testing was associated with higher use of AV treatment in appropriate target patients. Efforts are needed to understand AV use patterns and improve prescription rates in recommended patients. Disclosures All authors: No reported disclosures.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom